Neuro-Oncology News

Two-thirds of patients with relapsed pediatric low-grade glioma treated with tovorafenib responded to therapy, data released by the agent’s manufacturer showed.

The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.

The FDA granted accelerated approval to dabrafenib plus trametinib for treatment of certain patients with unresectable or metastatic solid tumors that harbor BRAF V600E mutations.

CHICAGO – Healio gathered the best, brightest and boldest group of oncologists during the ASCO Annual Meeting in Chicago to celebrate our inaugural Healio Disruptive Innovators.

In its 2022 Cancer Disparities Progress Report, American Association for Cancer Research discussed advances made in closing substantial gaps in care while underscoring the need for further progress.

CHICAGO — The addition of veliparib to adjuvant temozolomide did not extend OS or PFS among patients with newly diagnosed MGMT hypermethylated glioblastoma, according to results of a randomized phase 2/phase 3 trial presented at ASCO Annual Meeting.

CHICAGO — A combination of two targeted therapies significantly improved outcomes compared with standard care for children with BRAF V600 mutation-positive low-grade glioma, according to study results presented at ASCO Annual Meeting.

ASCO and the Association of Community Cancer Centers have jointly developed recommendations for improving equity, diversity and inclusion in cancer clinical trials.

May is Brain Cancer Awareness Month.

Although most cancer centers may not screen every patient at every visit, I believe in it whole-heartedly, and this is what we do at Rush University. If we believe in the value of asking patients how they are doing, it’s hard to justify excluding certain visits from this practice, particularly considering we aren’t very good about predicting when any individual patient might be struggling.